ClinicalTrials.gg
CompletedNCT03244228Updated Nov 29, 2019

A Two Part Study to Assess Safety, PK, PD, and Food Effect of Oral HTL0016878

A Phase 1 interventional study of HTL0016878 and Placebo - Concentrate in Healthy, sponsored by Nxera Pharma UK Limited. Completed at 1 site in United Kingdom. Per ClinicalTrials.gov, last updated 2019-11-29.

Sponsored by Nxera Pharma UK Limited · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
120
Allocation
Randomized
Sex
All
01

Study summary

Phase 1, first in human, two-part, single centre, placebo-controlled, single and multiple ascending dose trial in healthy younger and elderly adult subjects, with an open-label, randomised, crossover arms to assess the effect of food on bioavailability.

Read the detailed description

This is a first in human single and multiple ascending dose study with the objective to evaluate safety, tolerability, PK, PD, and food effect of HTL0016878 in healthy younger and elderly subjects. Part 1 will assess single doses of HTL0016878 and Part 2 will assess multiple doses of HTL0016878. Part 1 will be divided into 3 sub-parts: Part 1a will assess single ascending doses (SAD) of HTL0016878 in younger adult subjects, Part 1b will evaluate the effect of food on bioavailability of HTL0016878 and part 1c will investigate the effect of age on the PK of HTL0016878. Part 1c will only proceed after review of safety, tolerability and PK data from part 1a. Part 2 will be divided into 2 sub-parts to assess multiple ascending doses (MAD) of HTL0016878 in younger adult (part 2a) and elderly adult (part 2b) subjects. Part 2 will only proceed after review of safety, tolerability and PK data from Parts 1a, b and c.

02

Conditions studied

  • Healthy

Keywords

  • First in human
  • Multiple ascending dose
  • Single ascending dose
03

In context

Lead sponsor

Nxera Pharma UK Limited is the lead sponsor of 14 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Normotensive 18-55 year old (Parts 1a, 1b and 2a only) or 65+ year old (Parts 1c and 2b) male (all parts) or female (parts 1b, 2a and 2b only) volunteers with a 18-32kg/m².
  • Healthy on the basis of a clinical history, physical examination, (ECG), vital signs, heart rate (part 1a only), exercise history (part 1a only), and laboratory tests of blood and urine.
  • Willingness to comply with requirements or the trial, including requirements.
  • Able to give fully .

Exclusion criteria

Exclusion Criteria:

  • Positive tests for \& C,
  • severe adverse reaction to any drug
  • sensitivity to trial medication
  • drug or alcohol abuse
  • smoking
  • use of medication that inhibits CYP2D6 within previous 21 days or other prescribed and over-the-counter medication and herbal remedies within previous 21 days before dosing (with the exception of acetaminophen, medications and hormone replacement therapy), unless the principal investigator (PI) considers that it would not interfere with trial
  • participation in other clinical trials of unlicensed medicines in the previous 3 months, or regularly take part in more than 4 studies a year
  • loss of more than 500 mL blood in the previous 3 months
  • vital signs, interval or laboratory values outside the acceptable range
  • poor metabolizers of CYP2D6 (apart from one optional cohort in Part 1a, which may enrol poor metabolizers only)
  • abnormal findings at the screening assessment
  • acute or chronic illness
  • history of epilepsy or seizures
  • clinically relevant abnormal medical history or concurrent medical condition
  • disease associated with cognitive impairment and/or psychosis
  • recent history of suicidal thoughts or ideation, or insomnia
  • excessive use of caffeine containing beverages, exceeding 8 cups of coffee or equivalent/day and the inability to refrain from the use of caffeine containing beverages whilst on the ward
  • consumption of cranberry, pomegranate, star fruit, grapefruit, pomelos, exotic citrus fruits or Seville oranges (including marmalade and juices made from these fruits) within 3 days before admission; possibility that volunteer will not cooperate
  • pre-menopausal females who are pregnant or lactating, or who are sexually active and not using a reliable method of contraception
  • Objection by the GP.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
120 participants (actual)

Study arms

  • Experimental
    Part 1a SAD HTL0016878/Placebo

    In Part 1a, single ascending doses of HLT0016878 or matching placebo will be administered to groups of 12 subject each (9 active, 3 placebo). Each subject will have up to four treatment sessions separated by an appropriate wash-out. Healthy, young, male subjects.

    Drug: HTL0016878 · Drug: Placebo - Concentrate

  • Experimental
    Part 1b single dose HTL0016878

    In Part 1b, a single dose of HTL0016878 will be administered to 6 subjects on two occasions: once in the fasted and once the fed state. This will be open-label. Healthy, young, male or female subjects.

    Drug: HTL0016878

  • Experimental
    Part 1c single dose HTL0016878

    In Part 1c, a single dose of HTL0016878 will be administered to up to 6 (optional up to 12) healthy elderly subjects This will be open-label. Healthy, elderly, male subjects.

    Drug: HTL0016878

  • Experimental
    Part 2a MAD HTL0016878/Placebo

    In Part 2a, multiple doses of HTL0016878 will be administered to up to 5 cohorts (N=8, 6 active, 2 placebo) during one study session of 7 days. Healthy, young, male or female subjects.

    Drug: HTL0016878 · Drug: Placebo - Concentrate

  • Experimental
    Part 2b MAD HTL0016878/Placebo

    In Part 2b, multiple doses of HTL0016878 will be administered to up to 3 cohorts of healthy, elderly subjects (N=8, 6 active, 2 placebo) during one study session of 7 days. Healthy, young, male or female subjects.

    Drug: HTL0016878 · Drug: Placebo - Concentrate

Interventions

  • Oral solution

  • DrugPlacebo - Concentrate

    Matching placebo

06

What researchers measure

Primary outcomes

  1. Treatment emergent adverse events (TEAEs)

    Safety and Tolerability

    Time frame: Baseline up to 14 days post dose

  2. Physical examinations

    Safety and Tolerability

    Time frame: Baseline up to 14 days post dose

  3. vital signs (Heart Rate and Blood pressure)

    Safety and Tolerability

    Time frame: Baseline up to 14 days post dose

  4. Laboratory safety assessment

    Safety and Tolerability

    Time frame: Baseline up to 14 days post dose

  5. ECG

    Safety and Tolerability

    Time frame: Baseline up to 14 days post dose

  6. Columbia- suicide severity rating scale (C-SSRS)

    Safety and Tolerability

    Time frame: Baseline up to 14 days post dose

Secondary outcomes

  1. Maximum plasma concentration (Cmax) of HTL0016878

    Pharmacokinetics

    Time frame: Baseline up to 14 days post dose

  2. Time to Maximum plasma concentration (Tmax) of HTL0016878

    Pharmacokinetics

    Time frame: Baseline up to 14 days post dose

  3. Area under the curve of HTL0016878

    Pharmacokinetics

    Time frame: Baseline up to 14 days post dose

  4. Half-life (t1/2) of HTL0016878

    Pharmacokinetics

    Time frame: Baseline up to 14 days post dose

  5. Amount excreted in urine (Ae) of HTL0016878

    Pharmacokinetics

    Time frame: Baseline up to 14 days post dose

  6. Fraction of dose eliminated unchanged on urine (fe/F) of HTL0016878

    Pharmacokinetics

    Time frame: Baseline up to 14 days post dose

07

Study locations

1 site
  • Hammersmith Medicines Research
    London, Hammersmith NW10 7EW, United Kingdom
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2017 to primary completion in Sep 2019, 24 months.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 3, 2017
First posted
Aug 9, 2017
StartActual
Aug 25, 2017
Primary completionActual
Sep 23, 2019
CompletionActual
Sep 23, 2019
Last update
Nov 29, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 29, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03244228
Lead sponsor
Nxera Pharma UK Limited
Collaborators
Allergan
Responsible party
Sponsor
First posted
Aug 9, 2017
Start date
Aug 25, 2017
Primary completion
Sep 23, 2019
Completion
Sep 23, 2019
Last update
Nov 29, 2019

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Direclidine

Start the discussion